iTonic Holdings (ITOC)

The company’s core offering is the Beijing Feitian Treatment Planning System, software designed to help physicians and medical physicists plan brachytherapy procedures. Treatment planning is a critical part of radiation oncology because it helps determine source placement, dosage distribution, and the overall safety and effectiveness of a procedure. In brachytherapy, where accuracy is essential, planning tools are used to support consistent clinical decision-making and improve procedural control.

iTonic Holdings also supplies related medical auxiliary products used alongside brachytherapy systems. These include seed implant needles, computer workstations, patient positioning devices, and other supporting materials used in treatment preparation and delivery. This combination of software and procedure-related supplies positions the company within a specialized segment of the oncology equipment market rather than as a broad medical-device manufacturer.

For investors, iTonic Holdings represents exposure to the cancer treatment technology space, particularly in radiotherapy applications that require precision planning and dedicated clinical infrastructure. Its prospects are tied to hospital adoption of brachytherapy solutions, regulatory requirements for medical devices, demand for oncology treatment capacity, and the company’s ability to maintain reliable products for healthcare providers.